OR WAIT null SECS
The American Diabetes Association, together with the American Association of Clinical Chemistry, has released a new, 49-page document outlining optimized guidance for use of laboratory analysis in the diagnosis and management of diabetes.
The American Diabetes Association (ADA) has released new guidance for the use of laboratory analysis in the diagnosis and management of diabetes.
Released jointly with the American Association of Clinical Chemistry (AACC), the document was created to provide guidance aimed at streamlining the diagnostic process, standardizing laboratory procedures, and ensuring people with diabetes receive the most comprehensive and accurate care.1,2
"Scientific advances, particularly in the field of laboratory diagnostics, have necessitated a reassessment of our existing guidelines,” said Robert Gabbay, MD, PhD, the chief scientific and medical officer of the ADA. “Our goal with these updates is to empower healthcare providers with the latest tools and knowledge for accurate, early diagnosis, and optimal management of diabetes."
In the past decade, even dating back to the turn of the century, few fields with such immense public health implications have seen the level of interest and scientific advancement as the management of diabetes. Despite these advances in technology, pharmacotherapies, and management practices, the community has encountered major hurdles in their pursuit of optimized care, namely the increasing prevalence of both type 1 and type 2 diabetes.3,4
Approved by the AACC’s Evidence Based Laboratory Medicine Subcommittee in January 2023, the AACC Academy Council in February 2023, the AACC Board of Directors in March 2023, and the ADA in March 2023, the document, titled “Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus,”, was simultaneously published in Diabetes Care and Clinical Chemistry. At 49 pages in length and citing more than 500 references, the document represents both organization’s latest efforts at streamlining diagnosis and management of diabetes.1,2
The document itself contains dozens of recommendations, ranging in strength from strongly recommended to good practice to point, across 12 aspects of diagnosis and management. These 12 aspects include glucose, glucose meters, continuous glucose monitoring, noninvasive glucose sensing, gestational diabetes mellitus, urine glucose, ketone testing, HbA1c, genetic markers, autoimmune markers, urine albumin, and miscellaneous potentially important analytes.1,2
Some of the highest strength recommendations from within the document are highlighted below:1,2
"Applying this new guidance not only enhances diagnostic accuracy but also aids in risk stratification as well as helping clinicians tailor treatment plans,” said Nuha El Sayed, MD, MMSc, vice president of Healthcare Improvement and chair of the Professional Practice Committee of the ADA.